Get startedLog in
    Picture of Alligator Bioscience AB logo

    ATORX — Alligator Bioscience AB News Story

    0.000.00%
    se flag iconLast trade - 00:00
    HealthcareHighly SpeculativeMicro CapSucker Stock
    All News

    Brief: Alligator Bioscience Says Henlius Biotech Gets FDA IND Clearance For Phase 3 Initiation To Evaluate HLX22 (Ac101) In 1st Line HER2+ Advanced Gastric Cancer

    Picture of Alligator Bioscience AB logoAlligator Bioscience AB
    21/05/2024 11:09
    May 21 (Reuters) - Alligator Bioscience AB  ATORX.ST :
    * ANNOUNCES HENLIUS BIOTECH HAS RECEIVED FDA IND CLEARANCE
FOR
PHASE 3 INITIATION TO EVALUATE HLX22 (AC101) IN 1ST LINE HER2+
ADVANCED GASTRIC CANCER
    * FDA IND FOLLOWS PROMISING PHASE 2 RESULTS PRESENTED AT
2024 ASCO
GI REVEALING THAT ADDITION OF HLX22 (AC101) TO BIOSIMILAR
TRASTUZUMAB AND CHEMOTHERAPY LED TO DOSE-DEPENDENT INCREASE IN
PROGRESSION FREE SURVIVAL

Source text for Eikon:  ID:nMFNmN4Cm 
Further company coverage:  ATORX.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))

    Recent news on Alligator Bioscience AB

    See all news